Cargando…

The Anthelmintic Drug Niclosamide and Its Analogues Activate the Parkinson's Disease Associated Protein Kinase PINK1

Mutations in PINK1, which impair its catalytic kinase activity, are causal for autosomal recessive early‐onset Parkinson's disease (PD). Various studies have indicated that the activation of PINK1 could be a useful strategy in treating neurodegenerative diseases, such as PD. Herein, it is shown...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barini, Erica, Miccoli, Ageo, Tinarelli, Federico, Mulholland, Katie, Kadri, Hachemi, Khanim, Farhat, Stojanovski, Laste, Read, Kevin D., Burness, Kerry, Blow, Julian J., Mehellou, Youcef, Muqit, Miratul M. K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Communications
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5901409/ https://www.ncbi.nlm.nih.gov/pubmed/29226533 http://dx.doi.org/10.1002/cbic.201700500

Ejemplares similares

Kinetin Riboside and Its ProTides Activate the Parkinson’s Disease Associated PTEN-Induced Putative Kinase 1 (PINK1) Independent of Mitochondrial Depolarization
por: Osgerby, Laura, et al.
Publicado: (2017)

Parkinson’s Disease: Are PINK1 Activators Inching Closer to the Clinic?
por: Mehellou, Youcef
Publicado: (2023)

PINK1 and Parkin – mitochondrial interplay between phosphorylation and ubiquitylation in Parkinson's disease
por: Kazlauskaite, Agne, et al.
Publicado: (2015)

Basal Mitophagy Occurs Independently of PINK1 in Mouse Tissues of High Metabolic Demand
por: McWilliams, Thomas G., et al.
Publicado: (2018)

Repurposing the anthelmintic drug niclosamide to combat Helicobacter pylori
por: Tharmalingam, Nagendran, et al.
Publicado: (2018)

Drug Repurposing of the Anthelmintic Niclosamide to Treat Multidrug-Resistant Leukemia
por: Hamdoun, Sami, et al.
Publicado: (2017)

Global ubiquitylation analysis of mitochondria in primary neurons identifies endogenous Parkin targets following activation of PINK1
por: Antico, Odetta, et al.
Publicado: (2021)

Aryloxy Diester Phosphonamidate Prodrugs of Phosphoantigens (ProPAgens) as Potent Activators of Vγ9/Vδ2 T-Cell Immune Responses
por: Kadri, Hachemi, et al.
Publicado: (2020)

Structure of PINK1 and mechanisms of Parkinson's disease-associated mutations
por: Kumar, Atul, et al.
Publicado: (2017)

Parkin is activated by PINK1-dependent phosphorylation of ubiquitin at Ser(65)
por: Kazlauskaite, Agne, et al.
Publicado: (2014)

PINK1-dependent phosphorylation of Serine111 within the SF3 motif of Rab GTPases impairs effector interactions and LRRK2-mediated phosphorylation at Threonine72
por: Vieweg, Sophie, et al.
Publicado: (2020)

The Anthelmintic Drug Niclosamide Induces Apoptosis, Impairs Metastasis and Reduces Immunosuppressive Cells in Breast Cancer Model
por: Ye, Tinghong, et al.
Publicado: (2014)

Drug Repurposing: The Anthelmintics Niclosamide and Nitazoxanide Are Potent TMEM16A Antagonists That Fully Bronchodilate Airways
por: Miner, Kent, et al.
Publicado: (2019)

Niclosamide from an anthelmintic drug to a promising adjuvant therapy for diabetic kidney disease: randomized clinical trial
por: El-fatatry, Basma Mahrous, et al.
Publicado: (2023)

New life for an old drug: In vitro and in vivo effects of the anthelmintic drug niclosamide against Toxoplasma gondii RH strain
por: Zhang, Ji Li, et al.
Publicado: (2018)

Ubiquitin and Parkinson's disease through the looking glass of genetics
por: Walden, Helen, et al.
Publicado: (2017)

Phosphoproteomic screening identifies Rab GTPases as novel downstream targets of PINK1
por: Lai, Yu‐Chiang, et al.
Publicado: (2015)

Discovery of catalytically active orthologues of the Parkinson's disease kinase PINK1: analysis of substrate specificity and impact of mutations
por: Woodroof, Helen I., et al.
Publicado: (2011)

A meeting of minds: Overcoming roadblocks in the development of therapies for neurodegenerative disorders
por: Muqit, Miratul M K, et al.
Publicado: (2009)

Design, synthesis and biological evaluations of niclosamide analogues against SARS-CoV-2
por: Juang, Yu-Pu, et al.
Publicado: (2022)

PINK1 is activated by mitochondrial membrane potential depolarization and stimulates Parkin E3 ligase activity by phosphorylating Serine 65
por: Kondapalli, Chandana, et al.
Publicado: (2012)

PINK1-Dependent Mitophagy Inhibits Elevated Ubiquitin Phosphorylation Caused by Mitochondrial Damage
por: Lambourne, Olivia A., et al.
Publicado: (2023)

Whole proteome copy number dataset in primary mouse cortical neurons
por: Antico, Odetta, et al.
Publicado: (2023)

The PINK1 Activator Niclosamide Mitigates Mitochondrial Dysfunction and Thermal Hypersensitivity in a Paclitaxel-Induced Drosophila Model of Peripheral Neuropathy
por: Jang, Hye-Ji, et al.
Publicado: (2022)

TigarB causes mitochondrial dysfunction and neuronal loss in PINK1 deficiency
por: Flinn, Laura J., et al.
Publicado: (2014)

The ProTide Prodrug Technology: From the Concept to the Clinic: Miniperspective
por: Mehellou, Youcef, et al.
Publicado: (2017)

Binding to serine 65-phosphorylated ubiquitin primes Parkin for optimal PINK1-dependent phosphorylation and activation
por: Kazlauskaite, Agne, et al.
Publicado: (2015)

The magic bullet: Niclosamide
por: Jiang, Haowen, et al.
Publicado: (2022)

Mapping of a N-terminal α-helix domain required for human PINK1 stabilization, Serine228 autophosphorylation and activation in cells
por: Kakade, Poonam, et al.
Publicado: (2022)

Niclosamide: Beyond an antihelminthic drug
por: Chen, Wei, et al.
Publicado: (2018)

The anthelmintic drug niclosamide induces GSK-β-mediated β-catenin degradation to potentiate gemcitabine activity, reduce immune evasion ability and suppress pancreatic cancer progression
por: Guo, Yangyang, et al.
Publicado: (2022)

Redeployment-based drug screening identifies the anti-helminthic niclosamide as anti-myeloma therapy that also reduces free light chain production
por: Khanim, F L, et al.
Publicado: (2011)

Anthelmintic niclosamide suppresses transcription of BCR-ABL fusion oncogene via disabling Sp1 and induces apoptosis in imatinib-resistant CML cells harboring T315I mutant
por: Jin, Bei, et al.
Publicado: (2018)

Correction: The anthelmintic drug niclosamide induces GSK-β-mediated β-catenin degradation to potentiate gemcitabine activity, reduce immune evasion ability and suppress pancreatic cancer progression
por: Guo, Yangyang, et al.
Publicado: (2022)

On Anthelmintics
Publicado: (1875)

A Versatile Strategy for the Semisynthetic Production of Ser65 Phosphorylated Ubiquitin and Its Biochemical and Structural Characterisation
por: Han, Cong, et al.
Publicado: (2015)

Binding interactions of niclosamide with serum proteins
por: Maltas, Esra
Publicado: (2014)

Niclosamide for Covid-19: bridging the gap
por: Al-kuraishy, Hayder M., et al.
Publicado: (2021)

Antitumor effect and metabonomics of niclosamide micelles
por: Hang, Jiarong, et al.
Publicado: (2022)

Synthesis and biological evaluation of niclosamide PROTACs
por: Munoz, Erick, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ua40g4tv0dfhpp9ft2ra9qinui